The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued products.
GlobalData tracks 25 drugs in development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by 21 companies/universities/institutes. The top development phase for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is phase iii with eight drugs in that stage. The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline has 25 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline products market are: Argenx, Johnson & Johnson and Takeda Pharmaceutical.
The key targets in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline products market include IgG Receptor FcRn Large Subunit p51, Complement C1s Subcomponent, and Tumor Necrosis Factor Receptor Superfamily Member 17.
The key mechanisms of action in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline product include IgG Receptor FcRn Large Subunit p51 Antagonist with five drugs in Pre-Registration. The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline products include six routes of administration with the top ROA being Intravenous and ten key molecule types in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline products market including Monoclonal Antibody, and Antibody.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) overview
Chronic inflammatory demyelinating polyneuropathy (CIDP), also called as chronic relapsing polyneuropathy, is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal; orthostatic dizziness; and tingling and numbness of hands and feet.
For a complete picture of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
